The Experts below are selected from a list of 219 Experts worldwide ranked by ideXlab platform
Margaret M. Byrne - One of the best experts on this subject based on the ideXlab platform.
-
Factors related to Menopausal Symptom management decisions
Maturitas, 2011Co-Authors: Janet S. Carpenter, Margaret M. Byrne, Jamie L. StudtsAbstract:Abstract Objective To systematically review the literature regarding factors related to women's Menopausal Symptom management decision making. Methods The PubMed.gov online search engine was queried using pre-selected inclusion and exclusion criteria. Reference lists of articles were also reviewed to identify potentially missed articles. Full-text, English-language, peer-reviewed articles on factors related to Menopausal Symptom management decisions were reviewed. Results A total of 16 articles (15 data-based, 1 review of literature) from 6 different countries were reviewed. Most articles were related to decisions about one class of therapies and did not take into account all available therapeutic options. In the 15 data-based articles, diverse methods were used: qualitative (47%), quantitative (47%), and mixed (6%), with most being cross-sectional (93%). Very few of the data-based articles were based on a conceptual model (20%) and none used findings to derive an explanatory or predictive model. Most samples were not representative of special populations, such as women with breast cancer. Factors fell into four broad categories: (1) individual characteristics (demographics, menopause experience, Symptomatology); (2) values, attitudes, beliefs, and preferences (attitudes and beliefs about menopause and treatments, preferred modalities, tolerance for risks/side effects); (3) facts and information about menopause and Symptom management (amount, type, source, credibility, availability); and (4) health care context (health care provider communication, trust, availability/time, knowledge, relationship). Conclusions Additional descriptive studies are needed understand women's Menopausal Symptom management decisions in the context of all available therapies so that a comprehensive model of Menopausal Symptom management decision making can be specified. Additional understanding is needed regarding decisions in special populations of Menopausal women such as breast cancer survivors, a group for whom Menopausal Symptom management can be particularly complex.
-
a systematic review of Menopausal Symptom management decision aid trials
Maturitas, 2011Co-Authors: Janet S. Carpenter, Jamie L. Studts, Margaret M. ByrneAbstract:Abstract Objective To systematically review the literature regarding the effects of Menopausal Symptom management decision aids. Methods Using pre-designated inclusion and exclusion criteria, relevant articles were located using the PubMed.gov online search engine and reviewing reference lists of relevant articles. Full-text, English-language, peer-reviewed articles relevant to testing decision aids in uncontrolled trials (UCT) and randomized controlled trials (RCT) were reviewed. Results The 18 articles represented 15 trials focused on natural health products decision aids (1 UCT, 1 RCT) or hormone therapy decision aids (1 UCT, 12 RCT). Whereas the natural health products aid was intended for women deciding about Menopausal Symptom management strategies, decision aids for hormone therapy were intended for a broader group of Menopausal women and included indications for Symptom management, prevention of heart disease, and prevention of osteoporosis. Many trials occurred prior to two pivotal events: the 2002 announcement of the Women's Health Initiative findings and the 2006 publication of the International Patient Decision Aids Standards. Study limitations may help explain contradictory findings for outcomes such as decisional conflict, decisional confidence, decisional satisfaction, knowledge and values, and decisions. Conclusions There is a relatively scant contemporary literature related to Menopausal Symptom management decision aids. Additional methodologically sound studies are needed to develop and subsequently test decision aids that are based on (a) contemporary knowledge regarding the wide array of available therapies and (b) international standards for decision aids that include consideration of women's values and preferences.
Susan A. Ballagh - One of the best experts on this subject based on the ideXlab platform.
-
Vaginal Rings for Menopausal Symptom Relief
Drugs & Aging, 2004Co-Authors: Susan A. BallaghAbstract:The vagina is an alternative delivery site of sex steroids for Menopausal women. New ring technology provides continuous and consistent delivery of steroids for up to 3 months. Rings rest on the pelvic floor muscles in a nearly horizontal position and are usually imperceptible. Steroid is delivered directly into the systemic circulation which may result in less alteration of coagulation/fibrinolysis pathways as seen with transdermal hormone therapy. Fewer adverse effects are noted when progesterone is applied vaginally, possibly due to lower serum levels of metabolites such as alloprenanolone. Women often switch to a ring for the longer dosing interval but also appreciate the reduced messiness. Over 5700 healthy US women who evaluated an unmedicated ring as a drug delivery platform found it very acceptable independent of age or prior use of barrier contraceptives. Marketed rings in the US include: (i) a ring for systemic and vaginal Menopausal therapy that provides average serum estradiol levels of 40.6 pg/mL for the 0.05mg and 76 pg/mL for the 0.1mg dose; (ii) a ring for urogenital Menopausal Symptoms only that minimally elevates serum estradiol, usually within the Menopausal range, treating atrophic vaginitis and urethritis; and (iii) a ring labelled for contraception that provides ethinyl estradiol 15µg and etonogestrel 120µg appropriate for nonsmoking periMenopausal women. A ring for combination hormone therapy and another releasing progesterone for contraception in lactating women have been reported in the literature, but are not yet available commercially. These may offer future options for hormone therapy. Women with a uterus receiving estrogen, even in low doses, should be given progestogen to prevent endometrial hyperplasia or carcinoma. Even women who have had an endometrial ablation are likely to have some endometrial tissue remaining since long-term amenorrhoea is uncommon. Since no marketed combination ring product is available, other forms of progestogen are necessary. Vaginal rings offer a novel approach to Menopausal hormone therapy producing consistent serum levels sustained for up to 3 months per unit dose with lower adverse effects than other vaginal products and high acceptability among users.
-
vaginal rings for Menopausal Symptom relief
Drugs & Aging, 2004Co-Authors: Susan A. BallaghAbstract:The vagina is an alternative delivery site of sex steroids for Menopausal women. New ring technology provides continuous and consistent delivery of steroids for up to 3 months. Rings rest on the pelvic floor muscles in a nearly horizontal position and are usually imperceptible. Steroid is delivered directly into the systemic circulation which may result in less alteration of coagulation/fibrinolysis pathways as seen with transdermal hormone therapy. Fewer adverse effects are noted when progesterone is applied vaginally, possibly due to lower serum levels of metabolites such as alloprenanolone. Women often switch to a ring for the longer dosing interval but also appreciate the reduced messiness. Over 5700 healthy US women who evaluated an unmedicated ring as a drug delivery platform found it very acceptable independent of age or prior use of barrier contraceptives.
Janet S. Carpenter - One of the best experts on this subject based on the ideXlab platform.
-
Factors related to Menopausal Symptom management decisions
Maturitas, 2011Co-Authors: Janet S. Carpenter, Margaret M. Byrne, Jamie L. StudtsAbstract:Abstract Objective To systematically review the literature regarding factors related to women's Menopausal Symptom management decision making. Methods The PubMed.gov online search engine was queried using pre-selected inclusion and exclusion criteria. Reference lists of articles were also reviewed to identify potentially missed articles. Full-text, English-language, peer-reviewed articles on factors related to Menopausal Symptom management decisions were reviewed. Results A total of 16 articles (15 data-based, 1 review of literature) from 6 different countries were reviewed. Most articles were related to decisions about one class of therapies and did not take into account all available therapeutic options. In the 15 data-based articles, diverse methods were used: qualitative (47%), quantitative (47%), and mixed (6%), with most being cross-sectional (93%). Very few of the data-based articles were based on a conceptual model (20%) and none used findings to derive an explanatory or predictive model. Most samples were not representative of special populations, such as women with breast cancer. Factors fell into four broad categories: (1) individual characteristics (demographics, menopause experience, Symptomatology); (2) values, attitudes, beliefs, and preferences (attitudes and beliefs about menopause and treatments, preferred modalities, tolerance for risks/side effects); (3) facts and information about menopause and Symptom management (amount, type, source, credibility, availability); and (4) health care context (health care provider communication, trust, availability/time, knowledge, relationship). Conclusions Additional descriptive studies are needed understand women's Menopausal Symptom management decisions in the context of all available therapies so that a comprehensive model of Menopausal Symptom management decision making can be specified. Additional understanding is needed regarding decisions in special populations of Menopausal women such as breast cancer survivors, a group for whom Menopausal Symptom management can be particularly complex.
-
a systematic review of Menopausal Symptom management decision aid trials
Maturitas, 2011Co-Authors: Janet S. Carpenter, Jamie L. Studts, Margaret M. ByrneAbstract:Abstract Objective To systematically review the literature regarding the effects of Menopausal Symptom management decision aids. Methods Using pre-designated inclusion and exclusion criteria, relevant articles were located using the PubMed.gov online search engine and reviewing reference lists of relevant articles. Full-text, English-language, peer-reviewed articles relevant to testing decision aids in uncontrolled trials (UCT) and randomized controlled trials (RCT) were reviewed. Results The 18 articles represented 15 trials focused on natural health products decision aids (1 UCT, 1 RCT) or hormone therapy decision aids (1 UCT, 12 RCT). Whereas the natural health products aid was intended for women deciding about Menopausal Symptom management strategies, decision aids for hormone therapy were intended for a broader group of Menopausal women and included indications for Symptom management, prevention of heart disease, and prevention of osteoporosis. Many trials occurred prior to two pivotal events: the 2002 announcement of the Women's Health Initiative findings and the 2006 publication of the International Patient Decision Aids Standards. Study limitations may help explain contradictory findings for outcomes such as decisional conflict, decisional confidence, decisional satisfaction, knowledge and values, and decisions. Conclusions There is a relatively scant contemporary literature related to Menopausal Symptom management decision aids. Additional methodologically sound studies are needed to develop and subsequently test decision aids that are based on (a) contemporary knowledge regarding the wide array of available therapies and (b) international standards for decision aids that include consideration of women's values and preferences.
Jamie L. Studts - One of the best experts on this subject based on the ideXlab platform.
-
Factors related to Menopausal Symptom management decisions
Maturitas, 2011Co-Authors: Janet S. Carpenter, Margaret M. Byrne, Jamie L. StudtsAbstract:Abstract Objective To systematically review the literature regarding factors related to women's Menopausal Symptom management decision making. Methods The PubMed.gov online search engine was queried using pre-selected inclusion and exclusion criteria. Reference lists of articles were also reviewed to identify potentially missed articles. Full-text, English-language, peer-reviewed articles on factors related to Menopausal Symptom management decisions were reviewed. Results A total of 16 articles (15 data-based, 1 review of literature) from 6 different countries were reviewed. Most articles were related to decisions about one class of therapies and did not take into account all available therapeutic options. In the 15 data-based articles, diverse methods were used: qualitative (47%), quantitative (47%), and mixed (6%), with most being cross-sectional (93%). Very few of the data-based articles were based on a conceptual model (20%) and none used findings to derive an explanatory or predictive model. Most samples were not representative of special populations, such as women with breast cancer. Factors fell into four broad categories: (1) individual characteristics (demographics, menopause experience, Symptomatology); (2) values, attitudes, beliefs, and preferences (attitudes and beliefs about menopause and treatments, preferred modalities, tolerance for risks/side effects); (3) facts and information about menopause and Symptom management (amount, type, source, credibility, availability); and (4) health care context (health care provider communication, trust, availability/time, knowledge, relationship). Conclusions Additional descriptive studies are needed understand women's Menopausal Symptom management decisions in the context of all available therapies so that a comprehensive model of Menopausal Symptom management decision making can be specified. Additional understanding is needed regarding decisions in special populations of Menopausal women such as breast cancer survivors, a group for whom Menopausal Symptom management can be particularly complex.
-
a systematic review of Menopausal Symptom management decision aid trials
Maturitas, 2011Co-Authors: Janet S. Carpenter, Jamie L. Studts, Margaret M. ByrneAbstract:Abstract Objective To systematically review the literature regarding the effects of Menopausal Symptom management decision aids. Methods Using pre-designated inclusion and exclusion criteria, relevant articles were located using the PubMed.gov online search engine and reviewing reference lists of relevant articles. Full-text, English-language, peer-reviewed articles relevant to testing decision aids in uncontrolled trials (UCT) and randomized controlled trials (RCT) were reviewed. Results The 18 articles represented 15 trials focused on natural health products decision aids (1 UCT, 1 RCT) or hormone therapy decision aids (1 UCT, 12 RCT). Whereas the natural health products aid was intended for women deciding about Menopausal Symptom management strategies, decision aids for hormone therapy were intended for a broader group of Menopausal women and included indications for Symptom management, prevention of heart disease, and prevention of osteoporosis. Many trials occurred prior to two pivotal events: the 2002 announcement of the Women's Health Initiative findings and the 2006 publication of the International Patient Decision Aids Standards. Study limitations may help explain contradictory findings for outcomes such as decisional conflict, decisional confidence, decisional satisfaction, knowledge and values, and decisions. Conclusions There is a relatively scant contemporary literature related to Menopausal Symptom management decision aids. Additional methodologically sound studies are needed to develop and subsequently test decision aids that are based on (a) contemporary knowledge regarding the wide array of available therapies and (b) international standards for decision aids that include consideration of women's values and preferences.
Wonshik Chee - One of the best experts on this subject based on the ideXlab platform.
-
Ethnic differences in the clusters of Menopausal Symptoms.
Health care for women international, 2013Co-Authors: Wonshik CheeAbstract:Our purpose for this study was to identify clusters of midlife women by Menopausal Symptoms in a multiethnic sample, and to determine ethnic differences in the clusters. This was a secondary analysis of data from 501 women in a larger Internet study on Menopausal Symptom experiences. The data were analyzed using factor analysis, hierarchical cluster analysis, and multinominal logistic analysis. A three cluster solution was adopted (F = 575.71, p
-
“Symptom-Specific or Holistic”: Menopausal Symptom Management
Health care for women international, 2012Co-Authors: Hyenam Hwang, Wonshik CheeAbstract:Our purpose in this study was to identify differences in Menopausal Symptom management among four major ethnic groups in the United States. This was a secondary analysis of the qualitative data from a larger Internet-based study. We analyzed data from 90 middle-aged women in the United States using thematic analysis. We extracted four themes during the data analysis process: (a) “seeking formal or informal advice,” (b) “medication as the first or final choice,” (c) “Symptom-specific or holistic,” and (d) “avoiding or pursuing specific foods.” Health care providers need to develop Menopausal Symptom management programs while considering ethnic differences in Menopausal Symptom management.
-
subethnic differences in the Menopausal Symptom experience of asian american midlife women
Journal of Transcultural Nursing, 2010Co-Authors: Seung Hee Lee, Wonshik CheeAbstract:Purpose: To compare the Menopausal Symptom experiences of subethnic groups of Asian American midlife women. Design: A cross-sectional study among 91 Asian American women online. Questions about background characteristics, ethnic identity, and health and Menopausal status, and the Midlife Women’s Symptom Index were used. The data were analyzed using descriptive and inferential statistics. Findings: The most frequently reported and the most severe Symptoms differed by subethnicity. The total number of Symptoms differed by subethnicity, as did total severity scores for the Symptoms. Discussion, Conclusion, and Implications for Practice: Researchers and clinicians should be aware of subethnic differences.
-
A national multiethnic online forum study on Menopausal Symptom experience.
Nursing research, 2010Co-Authors: Bokim Lee, Wonshik Chee, Sharon L. Dormire, Adama BrownAbstract:Background:Little is known about how culture influences Menopausal Symptom experience, and few comparative qualitative studies have been conducted among multiethnic groups of midlife women in the United States. Objectives: The purpose of this study was to explore commonalities and differences in Menopausal Symptom experience among four major ethnic groups in the United States (Whites, Hispanics, African Americans, and Asians). Methods: This was a secondary analysis of qualitative data from a larger national Internet-based study. The qualitative data from 90 middle-aged women in the United States who attended four ethnic-specific online forums of the larger study were examined using thematic analysis. Results: The themes reflecting commonalities across the ethnic groups were just a part of life, trying to be optimistic, getting support, and more information needed. The themes reflecting the differences among the ethnic groups were open and closed, universal and unique, and controlling and minimizing. Overall, the findings indicated positive changes in women's Menopausal Symptom experience and supported the existence of cultural influences on women's Menopausal Symptom experience across the ethnic groups. Discussion: Systematic efforts need to be made to empower midlife women in their management of Menopausal Symptoms.
-
Menopausal Symptom experience of hispanic midlife women in the united states
Health Care for Women International, 2009Co-Authors: Hyun Ju Lim, Wonshik Chee, Sharon L. Dormire, Seung Hee Lee, Kimberly KrestaAbstract:Using a feminist approach, we examined the Menopausal Symptom experience of Hispanic midlife women in the United States This was a qualitative online forum study among 27 Hispanic midlife women in the United States. Seven topics related to Menopausal Symptom experience were used to administer the 6-month online forum. The data were analyzed using thematic analysis. Four themes were identified: (a) “Cambio de vida (change of life),” (b) “being silent about menopause,” (c) “trying to be optimistic,” and (d) “getting support.” More in-depth studies with diverse groups of Hispanic women are needed while considering family as a contextual factor.